Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nancy Eisenberger

Nurse Practitioner, Family Voorhees, NJ Nurse Practitioner

NPI 1548356868 CMS profile 10945339

2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043

Open in the dashboard

General payments

$82,079

292 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Eisenberger of Voorhees, NJ is reported in the CMS Open Payments database as having received $82,079 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,841 117
2024 General $11,861 66
2023 General $14,895 45
2022 General $20,874 48
2021 General $4,608 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Eisenberger
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Nancy Eisenberger were reported at $29,841. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Nancy Eisenberger Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,608 $124 $35–$379 $132
2022 $20,874 $141 $44–$430 $149
2023 $14,895 $154 $49–$476 $160
2024 $11,861 $165 $51–$504 $164
2025 $29,841 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $32,892 80 payments
  2. Janssen Scientific Affairs, LLC $29,561 42 payments
  3. Sobi, Inc $12,210 28 payments
  4. Eli Lilly and Company $2,100 1 payment
  5. AbbVie, Inc. $1,624 72 payments
  6. Amgen Inc. $952 22 payments
  7. Novartis Pharmaceuticals Corporation $846 4 payments
  8. Fresenius Kabi USA, LLC $750 2 payments
  9. UCB, Inc. $331 14 payments
  10. GlaxoSmithKline, LLC. $264 5 payments
  11. Other $547 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,141 39 payments
  2. Consulting Fee $17,476 12 payments
  3. Travel and Lodging $8,714 14 payments
  4. Food and Beverage $8,598 224 payments
  5. Education $150 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $54,760 106 payments
  2. SIMPONI ARIA $48,991 69 payments
  3. STELARA $24,957 33 payments
  4. RINVOQ $1,155 49 payments
  5. COSENTYX $846 4 payments
  6. IDACIO $750 2 payments
  7. SYNAGIS $589 4 payments
  8. EVENITY $357 9 payments
  9. SKYRIZI $315 15 payments
  10. Bimzelx $241 8 payments
  11. Other $1,889 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,847

Median for Nurse Practitioner: 389

Drug cost

$316,363

Median for Nurse Practitioner: $21,885

Branded share of claims

21.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 12 $116,446
Humira(Cf) Pen Adalimumab Brand 11 $88,984
Otezla Apremilast Brand 13 $62,786
Duloxetine Hcl Generic 414 $10,942
Hydroxychloroquine Sulfate Generic 226 $10,387
Methotrexate Methotrexate Sodium Brand 303 $10,335
Gabapentin Generic 315 $4,257
Colchicine Generic 19 $3,230
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 50 $2,262
Leflunomide Generic 38 $1,658

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$441,297

Of which drugs: $335,444

Medicare patients

561

Average age 74

Services billed

32,469

451 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 47%
Ischemic heart disease 31%
Diabetes 26%
Chronic kidney disease 20%
Depression 20%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 94 5,880 $117,873
Injection, golimumab, 1 mg, for intravenous use J1602 Office 17 3,700 $31,305
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 11 7,200 $25,612
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 153 1,108 $775
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 281 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $3,851
  • Janssen Scientific Affairs, LLC $207
$4,058 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $3,623
$3,623 — 3,700
SYNAGIS
  • Sobi, Inc $589
$589 — —
EVENITY
  • Amgen Inc. $271
$271 — —
RINVOQ
  • AbbVie, Inc. $188
$188 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record